Collectively, these results show that CD3+, CD4+, and CD8+ exhibit a higher sensitivity to CAP treatment than melanoma cells as they required lower doses of CAP to see its cytotoxic and anti-proliferative effects. This evidence concerns the gene CD4 and melanoma.